Updated Information About Rebiotix Punch CD 2 Trial
PUNCH™ CD 2 Study: A Clinical Trial For The Treatment Of Recurrent Clostridium difficile Infection Is Currently Enrolling Patients The PUNCH™ CD 2 study, sponsored by Rebiotix Inc., is open for enrollment and actively recruiting patients. This study represents Rebiotix progress toward developing and commercializing a new therapy to treat patients with recurrent episodes of … Read more